13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • M7824

    Acronym: 

    M7824

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase All phases Tumour Stream Non-small cell lung cancer
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase All phases
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Non-small cell lung cancer
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A multi-centre, double-blind, randomised, controlled study of M7824 with concurrent chemo-radiation followed by M7824 versus concurrent chemo-radiation plus placebo followed by durvalumab in participants with un-resectable stage III NSCLC

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Calvary Central Districts Hospital Julie Rowe julie.rowe@calvarycare.org.au 08 8239 9536 Not Yet Recruiting